真实世界研究:卡非佐米与硼替佐米治疗复发难治多发性骨髓瘤的肾脏缓解比较
本研究基于真实世界电子病历数据,比较卡非佐米-地塞米松(Kd)与硼替佐米-地塞米松(Vd)在复发难治多发性骨髓瘤(RRMM)伴肾功能不全患者中的肾脏缓解。纳入543例Kd和1005例Vd患者,二线治疗中Kd的肾脏总缓解率和完全缓解率显著高于Vd,且肾脏缓解与更长总生存和至下次治疗时间相关。
要点
- 二线治疗中Kd较Vd显著提高肾脏总缓解率(51.4% vs 39.6%)和肾脏完全缓解率(26.6% vs 22.2%)。
- 校正基线协变量后,二线Kd组达到肾脏总缓解的可能性是Vd组的1.45倍,肾脏完全缓解为1.68倍。
- 肾脏缓解者相比未缓解者具有更长的总生存和至下次治疗时间。
核心结论
- 真实世界数据表明Kd在RRMM肾脏挽救治疗中效果优于Vd,且肾脏缓解与生存改善正相关。
研究设计与样本
- 回顾性真实世界研究,数据来自Oncology Services Comprehensive Electronic Records数据库(2012年1月至2018年2月)。
- 纳入543例Kd治疗和1005例Vd治疗的RRMM患者(既往1-3线治疗,估算肾小球滤过率≤50 mL/min)。
主要发现
- 二线治疗中,Kd组肾脏总缓解率为51.4%,Vd组为39.6%(P < .0001);肾脏完全缓解率分别为26.6%和22.2%(P = .0229)。
- 校正基线协变量后,二线Kd组较Vd组肾脏总缓解的 incidence rate ratio 为1.45(95% CI 1.18-1.78),肾脏完全缓解为1.68(95% CI 1.24-2.28)。
- 肾脏缓解获益在二线至四线治疗中保持一致。
- 合并分析显示肾脏缓解者的总生存和至下次治疗时间均长于未缓解者。
关键数值与推荐
- 肾脏缓解根据国际骨髓瘤工作组(IMWG)标准定义。
- 肾脏总缓解率二线Kd组51.4% vs Vd组39.6%(P < .0001),肾脏完全缓解率26.6% vs 22.2%(P = .0229)。
- 校正后肾脏总缓解IRR 1.45(95% CI 1.18-1.78),肾脏完全缓解IRR 1.68(95% CI 1.24-2.28)。
临床怎么用
- 对于伴肾功能不全的RRMM患者,二线治疗选择Kd可能较Vd带来更高的肾脏缓解率。
- 肾脏缓解可作为临床获益的替代指标,与生存改善相关。
局限性
- 回顾性真实世界研究可能存在选择偏倚和混杂因素。
- 数据来源为电子病历数据库,可能存在信息缺失或记录不准确。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
In the phase 3 ENDEAVOR study, carfilzomib-dexamethasone (Kd) improved survival over bortezomib-dexamethasone (Vd) in patients with relapsed or refractory multiple myeloma (RRMM), regardless of baseline renal function. This real-world study compared renal response in patients with RRMM (1-3 prior lines) and renal impairment (estimated glomerular filtration rate ≤50 mL/min) treated with Kd vs Vd. Electronic medical records data from the Oncology Services Comprehensive Electronic Records database were assessed (from January 2012 through February 2018). Time to renal response (defined according to International Myeloma Working Group criteria) was evaluated using the Kaplan-Meier method and log-rank test. Incidence rate ratios (IRRs) and 95% confidence intervals (CIs) were calculated for renal overall response (ROR) and renal complete response (RCR) using Cox proportional hazard models adjusted for baseline covariates. Included were 543 Kd-treated and 1005 Vd-treated patients. In line 2 (2L), compared with Vd, Kd achieved significantly higher ROR (51.4% vs 39.6%; P < .0001) and RCR (26.6% vs 22.2%; P = .0229). After baseline covariate adjustment, 2L patients receiving Kd vs Vd were 45% more likely to achieve ROR (IRR, 1.45; 95% CI, 1.18-1.78), and 68% were more likely to achieve RCR (IRR, 1.68; 95% CI, 1.24-2.28). The renal response benefit with Kd remained consistent in 2L to line 4 (4L). In a combined analysis of patients receiving Kd and Vd (2L and 2L-4L), renal responders had longer overall survival and time to next treatment than renal nonresponders. These results demonstrate improved real-world effectiveness of Kd over Vd in RRMM renal rescue, and the positive association between renal response and improved survival.
引用
- Kumar S, Fu A, Niesvizky R, et al. Renal response in real-world carfilzomib- vs bortezomib-treated patients with relapsed or refractory multiple myeloma. Blood Adv. 2021. PMID: 33496733. doi:10.1182/bloodadvances.2019001059
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。